Xenetic Biosciences Reports Second Quarter 2026 Financial Results and ...
(PR-inside.com) Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategy Ongoing generation of translational data designed to support future clinical development and deepen understanding of DNase I-mediated NET targeting Continued royalty generation provides recurring, no…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


